A61P 35/02
Specific for leukemia
Official title: specific for leukemia
A61P35/02 (Specific for leukemia) appears on 17,309 US grants and 27,914 published applications in this corpus.
Search patents in A61P- Granted patents
- 17,309
- Published applications
- 27,914
- Assignees
- 6,095
- Inventors
- 39,084
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 3 | 0 |
| 1978 | 7 | 0 |
| 1979 | 3 | 0 |
| 1980 | 10 | 0 |
| 1981 | 5 | 0 |
| 1982 | 6 | 0 |
| 1983 | 11 | 0 |
| 1984 | 15 | 0 |
| 1985 | 11 | 0 |
| 1986 | 6 | 0 |
| 1987 | 15 | 0 |
| 1988 | 12 | 0 |
| 1989 | 22 | 0 |
| 1990 | 19 | 0 |
| 1991 | 13 | 0 |
| 1992 | 14 | 0 |
| 1993 | 16 | 0 |
| 1994 | 22 | 0 |
| 1995 | 34 | 0 |
| 1996 | 48 | 0 |
| 1997 | 60 | 0 |
| 1998 | 79 | 0 |
| 1999 | 98 | 0 |
| 2000 | 91 | 0 |
| 2001 | 144 | 54 |
| 2002 | 168 | 293 |
| 2003 | 198 | 527 |
| 2004 | 162 | 692 |
| 2005 | 162 | 701 |
| 2006 | 269 | 790 |
| 2007 | 298 | 887 |
| 2008 | 370 | 1064 |
| 2009 | 471 | 1335 |
| 2010 | 697 | 1592 |
| 2011 | 733 | 1553 |
| 2012 | 964 | 1575 |
| 2013 | 1171 | 1308 |
| 2014 | 1137 | 1457 |
| 2015 | 1035 | 1393 |
| 2016 | 1005 | 1492 |
| 2017 | 1090 | 1484 |
| 2018 | 984 | 1456 |
| 2019 | 1123 | 1440 |
| 2020 | 1019 | 1331 |
| 2021 | 849 | 1180 |
| 2022 | 681 | 1142 |
| 2023 | 548 | 1044 |
| 2024 | 547 | 879 |
| 2025 | 553 | 739 |
| 2026 | 309 | 506 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Composition containing buffer6 Oct 2026US 12,752,008 B2Perseus Proteomics Inc.
- Methods of culturing quiescent hematopoietic stem cells and treatment methods6 Oct 2026US 12,753,389 B2Icahn School of Medicine at Mount Sinai
- CD5 chimeric antigen receptor for adoptive T cell therapy29 Sep 2026US 12,746,273 B2Baylor College of Medicine
- Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof29 Sep 2026US 12,747,279 B2Abelzeta Inc.
- Haematopoietic stem/progenitor cells29 Sep 2026US 12,747,424 B2Murdoch Childrens Research Institute
- Combination therapy with clk/dyrk inhibitors and bcl2 inhibitors to treat leukemia8 Oct 2026US 2026/0306486 A1BioSplice Therapeutics, Inc.
- Triazolyl-containing compounds8 Oct 2026US 2026/0308146 A1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof8 Oct 2026US 2026/0308155 A1BeOne Medicines I GmbH
- Chimeric Cytokine Receptors and Methods of Use8 Oct 2026US 2026/0308235 A1
- Multispecific antibodies targeting cd3 and cd228 Oct 2026US 2026/0308255 A1
Most cited
By later US patents
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997
- Humanized immunoglobulins and methods of making the same1,467US 6,180,370 B2Protein Design Labs, Inc. · 2001
- Polypeptide variants with altered effector function1,378US 6,737,056 B1Genentech, Inc. · 2004